Glucose metabolism continuous deteriorating in male patients with human immunodeficiency virus accepted antiretroviral therapy for 156 weeks

Figure 4 Long-term dynamic changes in other glucose metabolism parameters within 144 wk after the initiation of antiretroviral therapy with tenofovir plus lamivudine plus efavirenz in male patients living with human immunodeficiency virus (n = 61). A: Fasting serum insulin level; B: Homeostasis model assessment of insulin resistance value; C: Homeostasis model assessment of β cell function value. ANOVA was used to compare glucose metabolism parameters from baseline to 144 wk (A, P < 0.0001; B, C, all P < 0.01). A paired t test was used to compare glucose metabolism parameters between baseline and specific follow-up time points, ^aP < 0.05, ^bP < 0.01.